Appendix B €C Gf

Appendix B €C Gf

Appendix B €C § Gf M Ameiucan Medical Association 535 NORTH DEARBORN STREET • CHICAGO. ILLIMOIS 60610 • PHONE (312) 751-6000 • TWX 910-221 0300 JAMMONS. M 0. tiecul'** Rreiidont (751 6200) September 3, 1981 Arthur Hull Hayes, Jr., M.D. Commissioner of Foods and Drugs 5600 Fishers Lane Rockville, Maryland 20857 RE: ■ Policy on Combination Prescription Drugs r* r r C-. oon irn Dear Commissioner Hayes: As v/e communicated to Secretary Schweiker in our letter of June 23, 1981, attached, the Amierican Medical Association is on record as agreeing that controlled clinical studies represent the best method of assessing drug efficacy and safety. We also believe, hoivever, that the accumulated experience of practitioners should be taken into account in determining the efficacy of drugs that have a long record (Df successful use in medical practice. This policy position is particularly applicable to combination prescription drugs where controlled studies may often be difficult, very coscly, and time-consuming to perform and evaluate. We recognize the difficulties faced by FDA in making final decisions about the continued marketability of the hundreds of combination drugs in the Drug Efficacy Study Implementation (DESI). In our view, it is n(3t always necessary for-FDA to insist on the conduct ot controlled clinical studies to provide "adequate evidence of effectiveness for such products. Instead, we believe FDA should evaluate all appropriate indices of efficacy -- including pnysician experience. To this end, "^he Am.erican Medical Association has prepared the attached suggested "Policy on Combination Prescription Drugs" which 'we urge the Agency to incorporate in its implementation of tlie existing regulation at 21 C.F.R. Sec. 300.50. As we conclude in this document. 000019 Dr. Hayes September 3, 1981 Page 2 which will be included in our comprehensive submission to your Task Force on Regulatory Reli.ef, "such a policy would likely be more cost-effective than the current policy, yet would not sacrifice any increment of public safety." ■Your prompt consideration of this request for a modification of existing policy standards v/ill be appreciated, Sincerely, James H.'Gammons, n,D, JHSrww Enclosures POLICY ON COMBINATION PRESCRIPTION DRUGS Citation 21 C.F.R. Sec. 300.50. Description The regulations in effect state, in part, that (a) Two or more drugs nay be combined in a single dosage form when each, component makes a contribution to the claimed dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient popu lation requiring such concurrent therapy as .defined in the labeling for the drug. AMA Concerns As a result of 1962 amendments to the Federal Food, Drug, and Cosmetic Act, FDA has been conducting efficacy evaluations of pre-1962 drugs, including combination prescription drugs, in the Drug Efficacy Study Implementation (DESI) program. FDA has 'interpreted and applied Sec. 300.50 to require that data from "well-controlled" clinical ives- tigations be produced to demonstrate efficacy when the accumulated medical literature to date does not contain such data, Such testing of long-used combination' drugs is highly complex scientifically and very costly. If a manufacturer does not undertake such studies and provide such data to FDA, FDA has been acting to withdraw the combination product's New Drug Application and remove the drug from the market. Impact Nothing in FDA's regulations at il C.F.R. Sec. 300.50 requires the clinical study protocols that are very costly, as well as difficult to design and evaluate, that FDA has recjiuested in the DESI review of these combination drugs in recent months. It is within FDA discretion to evaluate each DESI combination prescription drug individually based on all appropriate indices of efficacy. 0^ ■ • ■' ■ ■ ■ , . , . NORTH AMERICAN CLINICAL DERMATOLOGIC SOCIETY ' ' EXECUTIVE OFFICES—510 COMMONWEALTH AVE., BOSTON, MASS. 02215 '.L (r /'/v. PROGRAM DIRECTOR AND VICE PRESIDENT PRESIDENT VICE PRESIDENT ROBERT J. McNAMARA, M.D. JOHN T. McCarthy, m.d. CHARLES I. BLACK. M.D. 2028 TELEGRAPH AVE. 115 E filsl SrnEET 5220 FLANDERS DR. BERKELEY. CA 94705 NEW YORK. N V. 10021 BATON ROUGE, LA 70809 SECRETARY GENERAL COriRESPOtll5INr. SECRETARY TREASURER ■ EDMUND F. FINNERTY. M.D. DAVID W. POLAN. JR.. M.D. ROBERT D. HUBBARD. M.D. 510 COMMONWEALTH AVE. 520 COMMONWEALTH AVE. " 420 COURT STREET BOSTON. MASS. 02215 nOSTQN. MASS 02215 UTICA. N.Y. 13502 May 12, 1982 Marion B. Sulzberger, M.D. Committee on Use of Topical Medications 1567 Maple Ave. Evansto'n, 111. 60201 Dear Doctor Sulzberger: We are writing to clearly state the opinion of our one hundred sixty-five members, all of whom are active practicing dermatologists, that the proposed removal of combination topical agents would be a medical disaster for two reason,s: 1) The undoubted efficacy of combination products would O lead dermatologists to continue prescribing them - the Patient bearing the cost of compounding. 2) Compounding would be uneven at best. It is the unusual pharmacist who has had any significant experience in accurate compounding. Again, the patient suffers. We would respectfully refer you to the Editorial "Ban the Balm" Cutis 27:446, May 1981 and the forthcoming June Editorial in the same journal. Curiously, the absence of combination products would increase dermatologists referrals and thus there is no selfish motive involved in condemning^this ill advised Federal action. Respectfully submi-^ed, ¥ J/n- // ^ ( ^phn T. McCarthy, M.D. President Edmund T. Finnerty, M.D.' / -.'iVl Secretary Gene.ral JTM;EPF;j y-,nc. ■v.OV. ' .n ^^;vv;. : June 1, 1982 Jurs 3, ' John T. McCarthy, ?^,D. President American Clinical Dermatologic Sociptv 115 E. 6lst Street " ^ .New York, NY 10021 • ■ EdEStnd P. Pinnerty, r./I,D, Secretary General North American Clinical Dermatologic Society 510 Commonwealth Avenue ^ Boston, Mass, 02215 i Dear Drs, McCarthy and Finnertyj Your letter of May 12, I982 v/aa forwarded to me -from the office of the American Academy of Dermatology and reached me last Friday. As chairman of the ad hoc committee, preparing a statement to the FDA on the proposed removal of ..topical anti-infective agents by the PDA, I wish ito express to you the great encouragement that • • - your letter has given us. .. " opportunity arises, please convev my thanks ^d the thanks of my committee to the members of the North American Clinical Dermatologic Society. I do not know whether we will he atle to succeed in having the FDA reverse its decision about the removal of topical anti-infectivGS and combinations of such topical agents* However, if we, as physicians v/ho in the best jjosition to observe the effects of the medications we prescribe, do not express our convictions when government agencies propose to ban medicaments v;e have found useful, our patients v/ill vQ those v/hb suffer the most. • ■ '.1 . • "*■ ' •• ' V'" - , - ' - 2 - The opinions of your 165 members who are active practitlonGrs of dermatology will constitute Strong support for our position. There is a meeting of representatives of our ad hoc committee tomorrow, and I shall read your letter to them. Thank you again for writing as you did. Sincerely yours, ^^srion E. Sulzberger, iVi.D, CO. Peyton E. Weary, M.D. QQQ02* COMBINATION DRUG QUESTIONNAIRE American Academy of Dermatology, 1567 Maple, Evanston, IL 60201 NOTE TO RESPONDENTS: For purposes of this survey the following definitions will apply: growth or,^ oro"t ®to kill other micro-organisms.by a micro-organism which has the capacity to inhibit the COMBINATION - a formulation containing more than one active ingredient. Usually a steroid in combination with an anti-infective which is inhibiting to baclerii, fungi, or yeast. FOR QUESTIONS 1-8 PLEASE CHECK THE APPROPRIATE LINE FOR YOUR RESPONSE TO EACH ITEM. 1. Do you prescribe topical antibiotic combination drugs? Yes (1) No (2) 2. If "yes,"-how frequently do you prescribe them? Daily (1) Frequently (2) Occasionally (3) ; Rarely (4) 3. Do you prescribe steroid-antibiotic combinations? Yes (1) No (2) 4. If "yes," how often do you prescribe them? Daily (1) Frequently (2) Occasionally (3) Rarely (4) 5. Do you prescribe topical steroid-antifungal combination drugs? Yes (1) No (2) If "y®s," how often do you prescribe them? Daily (1) Frequently (2) Occasionally (3) Rarely (4) 7. Do you prescribe topical steroid-antiyeast combinations? Yes Cl) No (2) 8. If "yes," how often do you prescribe them? Daily (1) Frequently (2) Occasionally (3) Rarely (4) JUNE^ this QUESTIONNAIRE TO THE ACADEMY OFFICE NOT LATER THAN (cont'd) 000026 Page 2 PLEASE INDICATE FOR EACH OF THE FOLLOWING CONDITIONS, WHICH TOPICAL ANTIBIOTIC OR STEROID- ANTI-INFECTIVE AGENTS THAT YOU PRESCRIBE. CHECK EACH TREATMENT THAT APPLIES. (1) ■ (2) (3) (4) I Topical Steroid Steroid Steroid Antibiotics Antibiotic Antiyeast Antifungal Combination Combination Combination Combination 9. Atopic Dermatitis (9-12) 10. Secondarily Infected Eczema (13-16) 11. Secondarily Infected Dermatosis (17-20) 12. Intertrigo (21-24) 13. Impetigo (25-28) 14. Folliculitis (29-32) 15. Sycosis Barbae (33-36) 16. Paronychia (37-40) 17. Pustular Eruption of Hands and Feet (41-44) 18. Hailey-Hailey Disease (45-48) 19. Perleche (49-52) 20. Diaper Rash (49-52) 21. Moniliasis (57-60) 22. Tinea Facei (61-64) 23. Tinea Cruris (65-68) 24. Tinea Capitis (69-72) 25. Tinea Corporis (73-76) 26. Tinea Pedis (77-80) 27. Contact Dermatitis (81-84) 28. Otitis Externa (85-88) 29. Acne (89-92) 30. Rosacea (93-96) N 31. Tinea Versicolor (97-100) 00Q02? (cont'd) Page 3 OTHER (PLEASE SPECIFY) PLEASE INDICATE HOW OFTEN YOU HAVE PRESCRIBED THE FOLLOWING COMBINATION DRUGS IN THE LAST YEAR. CHECK ONLY ONE FOR EACH ITEM. 1 . 2 3 4 Frequently Occasionally Rarely Never 32. Bacitracin-Neoraycin (101) 33. Cor-Tar-quin® (102) 34.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    12 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us